Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Harris & Harris Group reports net asset value

Harris & Harris Group reports net asset value

August 17, 2005

The Company announced that in connection with a proposed public offering of shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission, as of today we have determined that our net asset value per share is $5.07. The increase of $7,952,716 in our net asset value since our most recently reported balance sheet data as of June 30, 2005, reflects an increase of $10,715,910 in the value of our shares in NeuroMetrix, Inc. (Nasdaq: NURO), minus an increase of $2,160,792 in our reserve for employee profit-sharing. For the purpose of the accrual, we calculate 20 percent of qualifying income pursuant to the terms of the profit-sharing plan and estimate the effect on qualifying income of selling all the portfolio investments that are valued above cost (i.e., are in an unrealized appreciation position). This methodology results in a fluctuation in our accrual but is not reflective of actual payments made under the profit- sharing plan. Profit-sharing plan payments require the existence of qualifying income and consider only realized gains and losses (unrealized gains are excluded.

Because our 1,137,570 shares of NURO, which went public in July 2004, are currently our most highly valued holding, the volatility of NURO's stock price is now a significant influence on our net asset value. NURO closed on August 16, 2005, at $29.45 per share, versus $20.03 per share on June 30, 2005.

####
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Registration Statement on Form N-2 (File No. 333-112862) and Annual Report on Form 10-K for the fiscal year ended December 31, 2004, each filed with the Securities and Exchange Commission, for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc.®, undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the website www.TinyTechVC.com has been provided as a convenience, and the information contained on such website is not incorporated by reference into this press release.

About Harris & Harris Group:
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS). The Company's last 24 initial private equity investments have been in tiny-technology enabled companies. As of today, the Company has 17,248,845 shares of common stock outstanding.

For more information, please visit www.TinyTechVC.com

Contact:
Charles E. Harris
(212) 582-0900

Copyright © Harris & Harris Group

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project